Aberrations of 6q13 Mapped to the COL12A1 Locus in Chondromyxoid Fibroma

Taketoshi Yasuda\*, Jun Nishio\*, Janos Sumegi, Kayla M. Kapels, Pamela A. Althof, Jeffrey R. Sawyer, John D. Reith, and Julia A. Bridge

Departments of Pathology and Microbiology (TY, JN, KMK, PAA, JAB), Pediatrics (JAB) and Orthopaedic Surgery (JAB), University of Nebraska Medical Center, Omaha, NE Department of Pediatrics (JS), Cincinnati Children's Hospital, Cincinnati, OH Department of Pathology (JRS), University of Arkansas for Medical Sciences, Little Rock, AR, Department of Pathology, Immunology, and Laboratory Medicine, Unit of Bone and Soft Tissue Pathology (JDR), University of Florida Health Sciences, Gainesville, FL

Abstract

Chondromyxoid fibroma, a rare benign bone tumor, may be mistaken for chondrosarcoma. Although cytogenetic studies of chondromyxoid fibroma are few, rearrangements of the long arm of chromosome 6 frequently expressed as an inv(6)(p25q13) are prominent. In this study, conventional cytogenetic analysis of 16 chondromyxoid fibroma samples from 14 patients revealed rearrangements of chromosome 6 in ten of eleven clonally abnormal specimens. In addition to 6q13 rearrangements, recurrent 6p25 and 6q25 anomalies were detected. Notably, an identical t(6;9)(q25;q22) translocation was identified in two cases suggesting it represents a distinct translocation of chondromyxoid fibroma. In an effort to further define the aberrant 6q13 breakpoint and identify the molecular consequences, a fluorescence in situ hybridization (FISH)-based positional cloning strategy on chondromyxoid fibroma abnormal metaphase and interphase cells using a series of bacterial and plasmid artificial chromosome (BAC/PAC) probe combinations spanning a 6.1 Mb region was employed. The breakpoint on 6q13 was located within the COL12A1 gene, a collagen gene purportedly involved in another benign bone tumor, subungual exostosis. The findings of this study expand our knowledge of chromosomal alterations in chondromyxoid fibroma, identify COL12A1 as the likely gene candidate within the recurrent 6q13 breakpoint, and provide an alternative approach for detecting 6q13 anomalies in nondividing cells of chondromyxoid fibroma. The latter could potentially be utilized as an adjunct in diagnostically challenging cases.

Keywords

chondromyxoid fibroma; cytogenetics; fluorescence in situ hybridization; COL12A1
Introduction

Chondromyxoid fibroma is a rare benign tumor of bone that was first described by Jaffe and Lichtenstein(1) in 1948. Chondromyxoid fibroma most commonly arises in the second and third decades of life(2,3) and typically involves the metaphysis of long bones. Histopathologically, the tumor is characterized by spindle shaped or stellate cells with round to oval nuclei and eosinophilic cytoplasm embedded in a myxoid or chondroid matrix.(4) Multinucleated osteoclast-like giant cells are often present at the periphery of the lobules. Approximately 18% of tumors show enlarged, hyperchromatic, and pleomorphic nuclei that may suggest malignancy, in particular chondrosarcoma.(3)

Few cases of chondromyxoid fibroma have been cytogenetically characterized.(5-15) Clonal abnormalities of chromosome 6 are prominent and have involved the following three recurrent breakpoints: 6p25, 6q13, and 6q25. A chromosome 6 pericentric inversion involving bands p25 and q13 has been described as the sole anomaly in two chondromyxoid fibromas(9,12) and as a component of more complex karyotypes in three other chondromyxoid fibromas.(8,9,11) In the current study, an identical inv(6)(p25q13) was detected in additional chondromyxoid fibroma cases, as well as a novel recurrent translocation t(6;9)(q25;q22).(10) Moreover, a detailed molecular cytogenetic investigation of the 6q13 breakpoint strongly suggesting the collagen gene COL12A1 is the target gene involved is reported.

Materials and methods

Tumor Samples

Sixteen chondromyxoid fibromas arising in 14 patients, six males and eight females, were included in the present study. The clinicohistopathologic features of the patients and corresponding tumors are listed in Table 1. The karyotypes for three of these patients have been reported previously (cases 8-10).(8,10) All cases were histologically characterized according to established criteria (Fig. 1).(2)

Cytogenetic Analysis

Cytogenetic analysis was performed on sterile, representative tissue of each case using standard culture and harvest procedures, as described previously.(16) Briefly, the tissues were disaggregated mechanically and enzymatically, and then cultured in RPMI 1640 medium supplemented with 20% fetal bovine serum for 3 to 7 days. Cells were exposed overnight to Colcemid (0.02 ug/ml). After subsequent hypotonic treatment (0.7% sodium citrate for 20 minutes), the preparations were fixed three times with methanol and glacial acetic acid (3:1). Metaphase cells were banded with Giemsa trypsin or Wright stain, and the karyotypes were expressed according to the International System for Human Cytogenetic Nomenclature.(17)
Probe Design

Molecular cytogenetic studies were conducted to further define the recurrent 6q13 breakpoint. This chromosomal band encompassing a 6.1 Mb region was subdivided into 21 segments that sequentially spanned the entire region (Fig. 2). Bacterial artificial chromosome (BAC) and P1-derived artificial chromosome (PAC) clones mapping to the chromosome band 6q13 region were identified from the NCBI Map Viewer (http://www.ncbi.nlm.nih.gov/mapview) and the Ensembl Genome Browser (http://www.ensembl.org). These clones were obtained from Children's Hospital Oakland Research Institute (Oakland, CA) and Research Genetics (Huntsville, AL). Combinations of probe sets were fashioned to flank each defined subregion.

Fluorescence in situ Hybridization (FISH)

FISH studies were performed on clonally abnormal metaphase cells or cytologic touch preparations of 13 chondromyxoid fibroma samples from 11 patients. Probes were directly labeled by nick translation with either Spectrum Green or Spectrum Orange-dUTP utilizing the manufacturer's protocol (Vysis, Abbott Molecular, Inc., Des Plaines, IL). An amount of 1 μg of DNA for each of two or three probes was combined. All nick translation reagents were then multiplied by the total ug of DNA used in the cocktail. Amounts of 200 ng of each probe were hybridized and blocked approximately 15 times with a combination of human Cot-1 DNA (Invitrogen, Carlsbad, CA) and human placental DNA. Spectrum aqua-labeled α-satellite probe for the centromeric region of chromosome 6 [CEP 6 (D6Z1), Abbott Laboratories Inc., Abbott Park, IL] was employed as a ploidy control.

Prior to hybridization, the touch preparations and in situ slides were pretreated in 2× saline sodium citrate (SSC) at 72°C for 2 min and in pepsin solution (20 μl 10% pepsin in 50 ml of 0.1 N hydrochloric acid) at 37°C for 3 min, washed in 1× phosphate-buffered saline (PBS) at room temperature for 5 min, fixed in 1% formaldehyde at 4°C for 5 min, and again washed in 1× PBS at room temperature for 5 min. The slides were then dehydrated in an ethanol series (70%, 85%, and 100%) at room temperature for 2 min each and air-dried. The cells and probes were codenatured at 75°C for 1 min and incubated at 37°C overnight using the HYBrite denaturation/hybridization system (Vysis). Post-hybridization washing was performed in 0.4× SSC/0.3% NP-40 at 72°C for 2 min, followed by 2× SSC/0.1% NP-40 at room temperature for 1 min. The slides were air-dried in the dark and counterstained with 4′, 6-diamidino-2-phenylindole (DAPI).

Each BAC or PAC clone was initially analyzed on metaphase and interphase cells of a karyotypically normal donor to confirm hybridization to the anticipated 6q13 locus with lack of cross-hybridization. Hybridization signals for each sample were assessed in 200 interphase nuclei or in 5 metaphase cells with strong, well-delineated signals by two different individuals. As additional controls, normal peripheral blood lymphocytes and cytologic touch preparations of pathologically unremarkable cartilage were simultaneously hybridized with the same probe sets. An interphase cell specimen was interpreted as abnormal for the 6q13 locus if a split of flanking probe signals was detected in >10% of the cells evaluated (more than two standard deviations above the average false positive rate).
Images were acquired using the CytoVision Image Analysis System (Applied Imaging, Santa Clara, CA).

Results

Conventional Cytogenetic Findings

The cytogenetic and FISH findings are summarized in Table 1. Clonal chromosomal abnormalities were detected in eleven of 16 specimens analyzed including ten involving chromosome 6 (Cases 1, 3a, 3b, 8a, 8b, 9, 10, 11, 12 and 13). Rearrangements of 6q13 were identified in three specimens, 6p25 in five specimens and 6q25 in five (note, an additional two specimens were suspect for a rearrangement of 6q25). Interestingly, two cases exhibited an identical 6;9 translocation \(t(6;9)(q25;q22)\) (Fig. 3).

Molecular Cytogenetic Findings

Initial FISH studies were performed on cytologic touch preparations of lesional tissue from Case 1 characterized by a cytogenetically confirmed inv(6)(p25q13) with 20 separate flanking probe combinations covering all 21 segments from the 6q13 breakpoint, 6.1 Mb region of interest. Only “region 20” (Spectrum Green-dUTP labeled proximal probes: RP11-560O20, RP11-536O4, RP1-238D15; Spectrum Orange-dUTP labeled distal probes: RP11-209D8, RP1-234P15) showed a split of the proximal and distal probe sets indicating a disruption of this 6q13 locus. Subsequent FISH studies performed on Case 1 abnormal metaphase cells with the “region 20” probe set confirmed a disruption of signals with translocation of the proximal probe set to 6p (Fig. 4a).

Thirteen additional chondromyxoid fibroma specimens subjected to FISH analysis with the “region 20” probe set showed a rearrangement of this locus in two cases (Cases 10 and 14). Case 14 exhibited a translocation of the distal probe set from one chromosome 6 homologue to the other chromosome 6 homologue at 6q27 (Fig. 4b). A split of one set of probe signals with loss of the probe set signal distal to “region 20” of the 6q13 breakpoint was identified in Case 10. The critical breakpoint bound by RP1-238D15 and RP11-209D8 of “region 20” at 6q13 is within the COL12A1 gene (Fig. 5). The remaining eleven specimens, none of which demonstrated a 6q13 rearrangement by conventional cytogenetic analysis, were negative by FISH for a rearrangement of this locus.

Discussion

Chondromyxoid fibroma is a rare benign bone tumor composed of immature myxoid mesenchymal tissue with features of early primitive cartilaginous differentiation.(4) Chondromyxoid fibroma most commonly arises as an eccentrically located, lytic lesion in the metaphysis of long tubular bones.(2) Histopathologically, chondromyxoid fibroma displays a pseudolobulated architecture with peripheral condensation of the neoplastic cells. (2,4) A thorough coordinated evaluation of clinical, radiological, and histological features generally leads to the correct diagnosis. In some cases, however, chondromyxoid fibroma may be mistaken for chondrosarcoma because of overlapping histopathologic traits including occasional pronounced cytologic atypia. Moreover, the use of minimally invasive biopsies to diagnose bone tumors has become increasingly common, and this shift has
created additional challenges. Recognition of novel diagnostic markers such as a tumor-specific chromosomal anomaly or gene rearrangement(s) could be useful in this respect.

Cytogenetic studies of chondromyxoid fibroma are few. To date, including the eleven specimens at our institution, 22 chondromyxoid fibroma specimens have reportedly shown clonal karyotypic anomalies (Table 2). (5-15) A diploid or near-diploid chromosomal complement has been observed in all cases analyzed. Chromosomal abnormalities involving 6q13 appear most frequent (11/22 specimens, 50%) followed by 6p25 (9/22, 41%) and 6q25 (8/22, 36%). An identical pericentric inversion, inv(6)(p25q13), has been detected in four chondromyxoid fibromas. (9,11,12) In accordance with previous reports, this aberration was also observed in a subset of the 6q13 aberrant tumors of the present series (Cases 1 and 20; as a component of a more complex anomaly in the latter case). In addition, a novel translocation, t(6;9)(q25;q22), was identified as the sole anomaly in Case 12 and as accompanied by a 7;12 translocation as the only other abnormality in Case 8 (10), suggesting it may represent a second diagnostic marker of chondromyxoid fibroma.

Given that the cytogenetic findings of the current study and a review of the literature indicated that the 6q13 locus is most commonly rearranged in chondromyxoid fibroma and likely harbors an oncogene of etiologic importance in this entity, efforts to further investigate this breakpoint were conducted. Metaphase and interphase FISH analyses revealed the key breakpoint lies within a 250 kb region located approximately 75.8–75.9 Mb from the telomere of 6p and flanked by RP1-238D15 and RP11-209D8 at 6q13. One gene, collagen type XII alpha 1 (COL12A1), is localized to this region of overlap (http://www.ncbi.nlm.nih.gov/mapview; http://www.ensembl.org), strongly suggesting its involvement in the development of chondromyxoid fibroma. Interestingly, another collagen gene, COL15A1, resides at 9q22 (18) and it could be speculated that this gene is involved in the recurrent 6;9 translocation identified in CMF cases lacking the inv(6)(p25q13).

The collagens constitute a large group of extracellular matrix proteins that can be divided into several distinct families. The COL12A1 gene encodes the alpha chain of type XII collagen. Type XII collagen is a member of the fibril-associated collagens with interrupted triple helices (FACIT) family and is composed of two short collagenous triple-helical domains and three non-triple-helical domains. (19) Although type XII collagen is expressed in a variety of connective tissues including articular and epiphyseal cartilage (20-24), its exact function remains poorly understood.

Recently, Storiazzi et al (25) demonstrated rearrangements of the COL12A1 and COL4A5 (at Xq22) gene loci in subungual exostoses with a t(X;6)(q22;q13-14). However, because these two genes are oriented in opposite directions (COL12A1 is transcribed from telomere to centromere whereas COL4A5 is transcribed from centromere to telomere), the authors concluded it was unlikely that these two genes fused to create a functional chimeric gene. Rather, they suggested that COL12A1 creates a fusion transcript with a different gene on the X chromosome, possibly IRS4.

On a similar theme, a different collagen associated gene COL1A1 (at 17q22), is fused to PDGFB (at 22q13) and USP6 (at 17p13) in dermatofibrosarcoma protuberans/giant cell...
fibroblastoma and aneurysmal bone cyst, respectively. (26, 27) For these neoplasms, the promoter region of COL1A1 is juxtaposed to the coding sequence of the fusion partner, thereby contributing to its transcriptional up-regulation by promoter swapping. If the same molecular mechanism were to be applied to chondromyxoid fibroma, then it would be expected that a fusion transcript derived from the rearrangements involving 6q13 [such as the inv(6)(p25q13) identified in a subset of these tumors] would be pathogenetic. In the present study, attempts to use the very limited quantity of extracted RNA available for identification of aberrant COL12A1 transcripts by RACE-PCR experiments failed (data not shown).

In conclusion, we have identified a consistent rearrangement of the COL12A1 gene in a subset of chondromyxoid fibromas karyotypically exhibiting 6q13 aberrations. The FISH probe sets utilized in this study represent an alternative approach for detecting 6q13 (COL12A1) rearrangements in nondividing cells of chondromyxoid fibroma as a potential adjunct in diagnostically challenging cases. In addition, we have discovered a second novel rearrangement, t(6;9)(q25;q22), as nonrandom in chondromyxoid fibroma. Additional studies afforded by sufficient fresh or frozen samples of this rare neoplasm are needed to further explicate how COL12A1 transcription is affected and its potential gene partners.

**Acknowledgments**

This work was supported in part by Nebraska State Department of Health (LB595) and NIH (P30 CA36727). Drs. Jun Nishio and Taketoshi Yasuda were supported by the Gladys Pearson Fellowship in Pediatric Cancer and Genetics. The authors would like to thank Ms. Kimberly Christian for her expert secretarial assistance and Ms. Marilu Nelson, Ms. Renae Streblow, Ms. Jamie Woodard, and Dr. Dali Huang for their technical assistance.

**References**

1. Jaffe HL, Lichtenstein L. Chondromyxoid fibroma of bone: distinctive benign tumor likely to be mistaken especially for chondrosarcoma. Arch Pathol. 1948; 45:541–551.
2. Unni, KK.; Inwards, CY.; Bridge, JA.; Kindblom, LG.; Wold, LE. Chondromyxoid fibroma. In: Silverberg, SG.; Sobin, LH., editors. AFIP Atlas of Tumor Pathology, Tumor of the Bones and Joints. ARP Press; Silver Spring: 2005. p. 67-73.
3. Wu CT, Inwards CY, O’Laughlin S, Rock MG, Beabout JW, Unni KK. Chondromyxoid fibroma of bone: a clinicopathologic review of 278 cases. Hum Pathol. 1998; 29:438–446. [PubMed: 9596266]
4. Ostrowski, ML.; Spjut, HJ.; Bridge, JA. Chondromyxoid fibroma. In: Fletcher, CDM.; Unni, KK.; Mertens, F., editors. WHO Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press; Lyon, France: 2002. p. 243-245.
5. Bridge JA, Sanger WG, Neff JR. Translocations involving chromosomes 2 and 13 in benign and malignant cartilaginous neoplasms. Cancer Genet Cytogenet. 1989; 38:83–88. [PubMed: 2713817]
6. Tarkkanen M, Bohling T, Helio H, et al. A recurrent chondromyxoid fibroma with chromosome aberrations ins(5;2)(q13;p21p25) and 2p deletion: a case report. Cancer Genet Cytogenet. 1993; 65:141–146. [PubMed: 8453600]
7. Halbert AR, Harrison WR, Hicks MJ, Davino N, Cooley LD. Cytogenetic analysis of a scapular chondromyxoid fibroma. Cancer Genet Cytogenet. 1998; 104:52–56. [PubMed: 9648559]
8. Sawyer JR, Swanson CM, Lukacs JL, Nicholas RW, North PE, Thomas JR. Evidence of an association between 6q13-21 chromosome aberrations and locally aggressive behavior in patients with cartilage tumors. Cancer. 1998; 82:474–483. [PubMed: 9452264]
9. Granter SR, Renshaw AA, Kozakewich HP, Fletcher JA. The pericentromeric inversion, inv(6) (p25q13), is a novel diagnostic marker in chondromyxoid fibroma. Mod Pathol. 1998; 11:1071–1074. [PubMed: 9831204]
10. Safar A, Nelson M, Neff JR, et al. Recurrent anomalies of 6q25 in chondromyxoid fibroma. Hum Pathol. 2000; 31:306–311. [PubMed: 10746672]

11. Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours: a report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol. 2002; 196:194–203. [PubMed: 11793371]

12. Sjögren H, Orndal C, Tingby O, Meis-Kindblom JM, Kindblom LG, Stenman G. Cytogenetic and spectral karyotype analyses of benign and malignant cartilage tumours. Int J Oncol. 2004; 24:1385–1391. [PubMed: 15138578]

13. Smith CA, Magenis RE, Himoe E, Smith C, Mansoor A. Chondromyxoid fibroma of the nasal cavity with an interstitial insertion between chromosomes 6 and 19. Cancer Genet Cytogenet. 2006; 171:97–100. [PubMed: 17116486]

14. Armah HB, McGough RL, Goodman MA, et al. UNM. Chondromyxoid fibroma of rib with a novel chromosomal translocation: a report of four additional cases at unusual sites. Diagn Pathol. 2007; 2:44. [PubMed: 18036245]

15. Jhala D, Coventry S, Rao P, Yen F, Siegal GP. Juvenile juxtacortical chondromyxoid fibroma of bone: a case report. Hum Pathol. 2008; 39:960–965. [PubMed: 18400252]

16. Althof PA, Ohmori K, Zhou M, et al. Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: aberrations of 17p mapped to 17p13.2 by fluorescence in situ hybridization. Mod Pathol. 2004; 17:518–525. [PubMed: 15044915]

17. Shaffer, LG.; Tommerup, N., editors. An International System for Human Cytogenetic Nomenclature. S. Karger; Basel: 2005.

18. Huebner K, Cannizzaro LA, Jabs EW, Kivirikko S, Manzone H, Pihlajaniemi T, Myers JC. Chromosomal assignment of a gene encoding a new collagen type (COL15A1) to 9q21-q22. Genomics. 1992; 14:220–224. [PubMed: 1427836]

19. Oh SP, Taylor RW, Gerecke DR, Rochelle JM, Seldin MF, Olsen BR. The mouse α1(XII) and human α1(XII)-like collagen genes are localized on mouse chromosome 9 and human chromosome 6. Genomics. 1992; 14:225–231. [PubMed: 1427837]

20. Watt SL, Lunstrum GP, McDonough AM, Keene DR, Burgeson RE, Morris NP. Characterization of collagen types XII and XIV from fetal bovine cartilage. J Biol Chem. 1992; 267:20093–20099. [PubMed: 1400327]

21. Oh SP, Griffith CM, Hay ED, Olsen BR. Tissue-specific expression of type XII collagen during mouse embryonic development. Dev Dyn. 1993; 196:37–46. [PubMed: 8334298]

22. Walchli C, Koch M, Chiquet M, Odermatt BF, Trueb B. Tissue-specific expression of the fibril-associated collagens XII and XIV. J Cell Sci. 1994; 107:669–681. [PubMed: 8207089]

23. Dharmavaram RM, Huyhn AI, Jimenez SA. Characterization of human chondrocyte and fibroblast type XII collagen cDNAs. Matrix Biol. 1998; 16:343–348. [PubMed: 9503368]

24. Gregory KE, Keene DR, Tufa SF, Lunstrum GP, Morris NP. Developmental distribution of collagen type XII in cartilage: association with articular cartilage and the growth plate. J Bone Miner Res. 2001; 16:2005–2016. [PubMed: 11697796]

25. Storiaazzi CT, Wozniak A, Panagopoulos I, et al. Rearrangements of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22). Int J Cancer. 2006; 118:1972–1976. [PubMed: 16284948]

26. Simon MP, Pedetour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberos and giant cell fibroblastoma. Nat Genet. 1997; 15:95–98. [PubMed: 8988177]

27. Oliveira AM, Perez-Ataye AR, Dal Cin P, et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene. 2005; 24:3419–26. [PubMed: 15735689]
Figure 1.
Chondromyxoid fibroma from case 1 exhibiting a pseudolobulated growth pattern of stellate or spindle-shaped cells in a myxoid stroma with zones of greater cellularity at the periphery of the lobules.
Figure 2.
This schematic illustrates the different probe set combinations used to sequentially examine 20 subdivided regions spanning a 6.1 Mb sector. The green boxes indicate probe sets labeled in Spectrum Green and the red boxes indicate probe sets labeled in Spectrum Orange.
Figure 3.
Schematic and partial G-banded karyotype illustrating the recurrent 6;9 translocation identified in Cases 8 and 12.
Figure 4.
(a) Representative schematic, G-banded and FISH partial karyotypes of the inv(6)(p25q13) observed in Case 1. With the inversion, the Spectrum Green labeled proximal probe set (RP11-560O20, RP11-536O4, and RP1-238D15) of “region 20” has moved to the short arm of chromosome 6. (b) Representative schematic, G-banded and FISH partial karyotypes of the complex rearrangement observed in Case 20. The Spectrum Orange labeled distal probe set (RP11-209D8 and RP1-234P15) of “region 20” has translocated from one chromosome 6 homologue to the other chromosome 6 homologue at 6q27. The aqua signals in both (a) and (b) represent the centromeric regions of the normal and derivative chromosome 6 homologues.
Figure 5.
Schematic representation of the breakpoint mapping of the COL12A1 locus. Three BACs, RP11-234P15 (blue), RP11-209D8 (red), and RP1-238D15 (green) cover the 5′ region, the middle section and the 3′ region respectively of the COL12A1 gene. Black vertical bars represent the exons and the red vertical bar the promoter region of COL12A1.Italicized numbers indicate the genomic position of the BACs and the COL12A1 gene. By FISH, the 6q13 breakpoint appears to be bound by the RP11-209D8 and RP1-238D15 BAC clones placing its location between exons 13 and 14 of COL12A1. The long yellow vertical bar depicts the position of the COL12A1 breakpoint on chromosome 6q13.
| Case | Age/Sex | Location | (Size in cm) | Karyotype | FISH† Results | ABN | NP |
|------|---------|----------|--------------|-----------|----------------|-----|----|
| 1    | 29/M    | Proximal tibia | (1.7 × 4.4 × 5.3) | 46,XY,inv(6)(p25q13)[3]/45,X,-Y,inv(6)(p25q13),-13,+mar[2]/46,XY[14] |  | N  |
| 2    | 32/F    | Second metatarsus | (0.5 × 1.0 × 1.5) | 46,XX[18] |  | N  |
| 3a   | 69/F    | Ilium | (3.3 × 4.0 × 4.5) | 48,XX,+der(6)del(6)(p11.2)del(6)(q12),+der(?)t(6;?;2;6)(?q25;?;q37q14.3;p12p25)[11]/49,idem,+der(6),del(13)(q21q33),[2]/96,idemx2[4]/46,XX[3].ish der(6)(wcp6+),der(?)t(6;?;2;6)(wcp6+,wcp2+,wcp6+) |  | N  |
| 3b   |         |         |              | 48,XX,+der(6)del(6)(p11.2)del(6)(q12),+der(?)t(6;?;2;6)(?q25;?;q37q14.3;p12p25)[10]/49,idem,+der(6)[5]/46,XX[3] |  | N  |
| 4    | 10/M    | Proximal humerus | (1.2 × 1.3 × 2.2) | 46,XY[18] |  | N  |
| 5    | 21/F    | Ilium | (5.3 × 5.5 × 7.0) | 46,XX[19] |  | N  |
| 6    | 12/M    | Proximal tibia | (2.0 × 2.3 × 2.3) | 46,XY[7] |  | N  |
| 7    | 23/M    | Ilium | N/A | 46,XY[20] |  | N  |
| 8a   | 55/F    | Proximal tibia | (2.5 × 6.0 × 6.3) | 46,XX,t(6;9)(q25;q22),t(7;12)(q32;q13)[15] |  | N  |
| 8b   |         |         |              | 46,XX,t(6;9)(q25;q22),t(7;12)(q32;q13)[10] |  | N  |
| 9    | 37/F    | Distal femur | N/A | 46,XX,del(3)(q23),t(4;6)(q21;q25)[7] |  | N  |
| 10   |         |         |              | 46,XY,inv(6)(p25q23)t(6;6)(q23;q13)[39],tas(15;21)(p13;p13)[6],tas(3;15)(q29;p13)[5],tas(11;15)(p15;p13)[5],r(15)[5][cp39] |  | ABN |
| 11   | 44/F    | Ulna | (1.2 × 1.3 × 2.2) | 46,XX,t(1;6)(p35;q25),inv(9)(p11q13)c[17]/46,sl,t(3;4)(p21;p16)[2]/46,XX,inv(9)(p11q13)[1] |  | NP |
| 12   | 55/M    | Distal tibia | (2.1 × 2.6 × 3.4) | 46,XY,t(6;9)(q25;q22)[20] |  | NP |
| 13   | 47/F    | Rib | (2.0 × 2.8 × 3.0) | 46,XX,t(1;16)(q11;q24),t(9;16)(p23;q12.1),del(13)(q13q22)[16]/46,XX,t(8;14)(q22;q13),t(11;17)(q14;q25)[2]/92sl1x2[2]/46,XX[2] |  | NP |
| 14   |         | Great toe, proximal phalanx | (0.8 × 0.8 × 1.2) | 46,XX,der(6)t(6;6)(q13;q27),der(6)t(6;6)inv(6)(p25q15)[8]/46,XX[12] |  | ABN |

N/A, not available; N, normal; ABN, abnormal; NP, not performed.

† All cases were primary lesions. Cases 3 and 8 included both biopsy and subsequent resection/curettage samples.

†† FISH conducted with the following probes: RP11-560O20, RP11-536O4, RP1-238D15, RP11-209D8, RP1-234P15.
These karyotypes have been reported previously. (8, 10)
| No. | Karyotype                                                                 | Reference                     |
|-----|---------------------------------------------------------------------------|-------------------------------|
| 1   | 46.X,Yt(2;13)(q14;33)(33),del(16)(p13),+X| Bridge et al(5)               |
| 2   | 46.XX,der(21)ins(21;21)(q13;12),del(22)(q13;12),+Y                      | Tarkkanen et al(6)            |
| 3   | 46,X,del(3)(q21),+Y                                                     | Hiltbert et al(7)             |
| 4   | 46.XX,t(6;11)(q25;p15)                                                   | Sawyer et al(8)               |
| 5   | 46.XY,t(6;12)(q12;p12)                                                   | Grantier et al(9)             |
| 6   | 46.XY,add(6)(p23)                                                       | Grantier et al(9)             |
| 7   | 46.XX,add(7)(q21)                                                       | Grantier et al(9)             |
| 8   | 46.XY,del(6)(p12)                                                       | Grantier et al(9)             |
| 9a  | 46.XXt(6;9)(q25;q13)                                                    | Safar et al(10)               |
| 9b  | 46.XX,del(6)(p23)                                                       | Safar et al(10)               |
| 10  | 46.XX,del(6)(q13)                                                       | Safar et al(10)               |
| 11  | 46.XX,del(6)(q13),add(7)(q21)                                            | Smith et al(13)               |
| 12  | 46.XX,del(6)(p23),add(6)(q13)                                            | Tallini et al(11)             |
| 13  | 46.XY,del(6)(q23),del(6)(p23),add(7)(q21)                                | Tallini et al(11)             |
| 14  | 46.XY,del(6)(q23),del(6)(p23),add(7)(q21)                                | Sjögren et al(12)             |
| 15  | 46.XXt(6;9)(q25;q13)                                                    | Aemati et al(14)              |
| 16  | 46.XX,del(6)(q13)                                                       | Jhala et al(15)               |
| 17  | 46.XX,del(6)(p23),del(6)(q13),del(6)(p23),del(6)(q13)                   | Current study                 |
| 18a | 48.XX,del(6)(p23),del(6)(p23),del(6)(p23),del(6)(p23),del(6)(p23)       | Current study                 |
| 18b | 48.XX,del(6)(p23),del(6)(p23),del(6)(p23),del(6)(p23),del(6)(p23)       | Current study                 |
| 19  | 46.XXt(6;9)(q23),del(6)(q13)                                            | Current study                 |
| 20  | 46.XX,del(6)(q23),del(6)(q13)                                            | Current study                 |
| 21  | 46.XX,t(10;16)(q25),del(11)(p13)                                         | Current study                 |
| 22  | 46.XX,del(6)(p23),del(6)(q13),del(6)(p23),del(6)(q13),del(6)(p23)       | Current study                 |

**Table 2**

Chromosomal findings in chondromyxoid fibroma